Testing effectiveness (Phase 2)UnknownNCT02927340
What this trial is testing
Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital 30